Answers are grounded in this paper and cite their sources.
Objectives: Severe refractory Mycoplasma pneumoniae pneumonia (SRMPP) remains a significant threat to pediatric patients. Doxycycline is recommended as an alternative treatment for pediatric SRMPP, while its pharmacokinetic (PK) profile in this specific population is still poorly characterized. This study aimed to characterize the PK profile of intravenous doxycycline by developing a population pharmacokinetic (PopPK) model in Chinese pediatric patients with SRMPP and to evaluate its exposure across different age groups. Methods: The residual blood samples were prospectively collected from patients aged ≤ 18 years receiving intravenous doxycycline for the treatment of SRMPP between April 2023 and April 2025 at the Children’s Hospital Affiliated to Zhengzhou University using the opportunistic sampling approach. Plasma concentrations of doxycycline were determined by high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS) and PopPK analysis was performed with the Phoenix NLME software. The steady-state areas under the concentration–time curve from 0 to 24 h (AUCss,0–24 h) of doxycycline were calculated based on Monte Carlo simulation results and compared between groups by geometric mean ratios (GMRs) with 90% confidence intervals (90% CIs). Results: A total of 81 doxycycline plasma concentrations from 68 pediatric patients aged 1.8 to 13.2 years with SRMPP receiving intravenous doxycycline were collected and included for the final PopPK analysis. A one-compartment PopPK model with first-order elimination best described the current data. Body weight was incorporated as the a priori covariate using allometric scaling (fixed exponents of 0.75 for CL and 1.0 for V) and no other screened covariates were identified to have a significant impact on CL or V. For the final model, the estimated typical values were 5.08 L/h/70 kg for CL and 56.57 L/70 kg for V, respectively. Using the 2 to <8 years group as the reference, the GMRs of AUCss,0–24 h in the 8 to 14 years group with BW < 45 kg and BW ≥ 45 kg were 1.10 (90% CI: 1.09–1.11) and 1.04 (90% CI: 1.03–1.05), among which the 90% CIs were fully contained within the prespecified equivalence margins (0.80, 1.25). Conclusions: This final PopPK model characterizes intravenous doxycycline PK profile in Chinese pediatric patients with SRMPP aged 2 to 14 years. Model-based simulations found that the currently recommended dosing regimens of intravenous doxycycline at 2.2 mg/kg every 12 h (a maximum of 200 mg/day every 12 h) yield comparable exposure across the 2 to <8 years group and the 8 to 14 years group.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: